Tag:

Treatments

In people with cystic fibrosis, some resistance to antibiotics caused by Pseudomonas aeruginosa may paradoxically increase bacterial virulence, complicating lung infections and opening the way to new therapeutic approaches.

The addition of Trikafta to the RAMQ in September 2021 marks a major advance for cystic fibrosis in Quebec by making available a treatment that acts on the cause of the disease for eligible people.

Research has profoundly improved the prognosis of cystic fibrosis thanks to CFTR modulators, with new hope for all patients despite challenges in accessing treatments.

This article provides a global portrait of the future of cystic fibrosis care, marked by major advances (CFTR modulators, early diagnosis, multidisciplinary care) but hampered by strong inequalities in access to treatments and growing challenges related to the aging of patients.

Manon Goulet testifies that it is possible to live with cystic fibrosis into your sixties by adapting to the disease, redefining your priorities and finding hope thanks to new treatments.

This study shows that delayed access to Trikafta would lead to more serious lung diseases, more exacerbations, more deaths, and significantly lower life expectancy in people with cystic fibrosis compared to early access.